Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
activist, Addendum, AI, analyzing, answer, arbitration, ATD, automated, BI, Boehringer, budget, CFO, cited, concentration, concomitant, Connecticut, Consortium, COO, David, deceptive, deep, Delinquent, deprive, diligence, disaster, East, elapsed, element, Excellence, FADP, fake, Florida, fluid, front, furlough, GmbH, grandfathered, Hilleman, Hong, incumbent, Ingelheim, intelligence, Interagency, IRP, Jeryl, Kong, Kupfer, leaked, lysosomal, Middle, misrepresentative, monumental, NICE, occasionally, outsourced, overruled, PDUFA, penetration, pharmacodynamic, predominantly, question, recovery, regular, reintegrated, resale, revealed, RTF, Scottish, shut, SI, SIP, SMC, sooner, sterling, subscribing, tailored, unexercised, Windsor
Filing tables
Filing exhibits
NERV similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement Nos. 333-267424 and 333-273686 on Form S-3 and Nos. 333-242460, 333-225672, 333-223593, 333-222368, 333-216637, 333-210147, 333-203738, and 333-198753 on Form S-8 of our report dated March 8, 2023, relating to the consolidated financial statements of Minerva Neurosciences, Inc. appearing in this Annual Report on Form 10-K for the year ended December 31, 2023.
/s/ DELOITTE & TOUCHE LLP
Boston, Massachusetts
February 22, 2024